Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of combination of lenvatinib and PD-1 monoclonal antibody in preparation of anti-hepatoma drugs

A technology of PD-1 and lenvatinib, applied in the field of medicine, can solve problems such as poor blood perfusion of tumor tissue

Pending Publication Date: 2022-03-18
SUN YAT SEN UNIV +1
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are a large number of abnormal blood vessels inside the liver cancer tissue, which will cause poor blood perfusion of the tumor tissue, limit the infiltration of T cells into the tumor tissue, and resist the efficacy of PD-1 monoclonal antibody

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combination of lenvatinib and PD-1 monoclonal antibody in preparation of anti-hepatoma drugs
  • Application of combination of lenvatinib and PD-1 monoclonal antibody in preparation of anti-hepatoma drugs
  • Application of combination of lenvatinib and PD-1 monoclonal antibody in preparation of anti-hepatoma drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] To explore the optimal dose of lenvatinib to improve vascular normalization of mouse liver cancer xenografts.

[0029] 1. Experimental materials

[0030] (1) Drug: lenvatinib (lenvatinib), its chemical formula is: C 21 h 19 ClN 4 o 4 , CAS number: 417716-92-8;

[0031] (2) Cancer cells: mouse liver cancer cells (Hepa1-6);

[0032] (3) Commercially available immunocompetent C57B / L mice.

[0033] 2. Experimental grouping

[0034] (1) Control group: blank control, that is, liver cancer tumor-bearing mice without any drug treatment;

[0035] (2) 3mg / kg / day lenvatinib group: use 3mg / kg / day lenvatinib to treat liver cancer tumor-bearing mice;

[0036] (3) 10mg / kg / day lenvatinib group: use 10mg / kg / day lenvatinib to treat liver cancer tumor-bearing mice;

[0037] (4) 30 mg / kg / day lenvatinib group: 30 mg / kg / day lenvatinib was used to treat liver cancer tumor-bearing mice.

[0038] 3. Subcutaneous tumor formation in immunocompetent C57B / L mice to detect the effects of d...

Embodiment 2

[0047] Effects of different doses of lenvatinib combined with PD-1 monoclonal antibody on the size of hepatocellular carcinoma xenografts.

[0048] 1. Experimental materials

[0049] (1) Drugs:

[0050] 1) Lenvatinib (lenvatinib), its chemical formula is: C 21 h 19 ClN 4 o 4 , CAS number: 417716-92-8;

[0051] 2) PD-1 monoclonal antibody: anti-mouse PD-1 (CD279);

[0052] (2) Cancer cells: mouse liver cancer cells (Hepa1-6);

[0053] (3) Commercially available immunocompetent C57B / L mice.

[0054] 2. Experimental grouping

[0055] (1) Control group: blank control, that is, liver cancer tumor-bearing mice without any drug treatment;

[0056] (2) Low-dose lenvatinib group: use low-dose lenvatinib to treat liver cancer tumor-bearing mice;

[0057] (3) High-dose lenvatinib group: use high-dose lenvatinib to treat liver cancer tumor-bearing mice;

[0058] (4) PD-1 monotherapy group: use PD-1 monoclonal antibody to treat liver cancer tumor-bearing mice;

[0059] (5) Low-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of combination of lenvatinib and a PD-1 monoclonal antibody in preparation of an anti-liver cancer drug, and belongs to the technical field of medicines.The combination of low-dose lenvatinib and the PD-1 monoclonal antibody is adopted, infiltration of T lymphocytes in tumor tissue can be enhanced while normalizing of liver cancer blood vessels is promoted, and then the treatment effect on liver cancer is remarkably enhanced; the compound can be applied to liver cancer prevention and treatment. The invention provides a novel treatment combined medication scheme for the treatment of the liver cancer, and has a good application prospect in the aspect of preventing and treating the liver cancer.

Description

technical field [0001] The invention relates to the field of medical technology, in particular to the application of lenvatinib combined with PD-1 monoclonal antibody in the preparation of anti-liver cancer drugs. Background technique [0002] According to the global cancer report published by WHO in 2020, primary hepatocellular carcinoma ("liver cancer") has become the sixth malignant tumor with the highest incidence rate and the third highest mortality rate in the world. Accounting for nearly 50% of the world, it has become the country with the largest number of liver cancer incidence and death in the world. Many patients with liver cancer have already lost the chance of radical treatment (such as surgery, liver transplantation or radiofrequency ablation) and local treatment such as chemoembolization, and the low sensitivity of liver cancer to systemic chemotherapy makes the prognosis of these patients very poor. Difference. Therefore, there is an urgent need to find new...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61K31/47A61P35/00
CPCA61K39/3955A61K31/47A61P35/00A61K2300/00C07K16/2818A61K39/39558A61K2039/505A61K2039/545
Inventor 向橦夏建川杨洁莹
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com